Table 3.
Potential Therapeutic Targets. Possible COVID-19 therapeutic targets based on targetability in similar diseases and prevalence in COVID-19 infection.
| Gene | Basic Functionality | Drug Target Evidence |
|---|---|---|
| ANPEP | Peptidase with increased activity in coronaviral infections | Unverified |
| CCL2 | Inflammatory cytokine upregulated in many viral infections | Unverified |
| HBB | Hemoglobin beta subunit that regulates inflammatory cytokines | Unverified |
| IFI27 | Interferon-induced protein upregulated in severe COVID-19 | Unverified |
| HLA-A | MHC Class I peptide upregulated in COVID-19 and liver injury | Unverified |
| HLA-B | MHC Class I peptide upregulated in COVID-19 and liver injury | Unverified |
| HLA-C | MHC Class I peptide upregulated in COVID-19 and liver injury | Unverified |
| IL-17A | Cytokine that is upregulated in severely infected patients | Use in other diseases |
| IL4R | Cytokine receptor that is upregulated in pulmonary disease | Use in other diseases |
| ALPI | Phosphatase that is upregulated in respiratory disease | Use in other diseases |
| MAPK8 | Kinase involved in apoptosis in SARS infections | Use in other diseases |
| SERPINC1 | Upregulated activity in cirrhosis of liver and COVID-19 | Validated COVID-19 Use |
| CCL7 | Inflammatory cytokine | Validated COVID-19 Use |
| AGTR1 | Increased activity appears in cirrhosis and SARS infections | Validated COVID-19 Use |
| TUBG2 | Structural molecule upregulated in viral infections | Validated COVID-19 Use |
| PPARG | Receptor upregulated in kidney injury and SARS infections | Validated COVID-19 Use |
| IL-6 | Pro-fibrotic factor and inflammatory cytokine | Validated COVID-19 Use |
| GABRA4 | GABA receptor with increased expression in SARS infections | Validated COVID-19 Use |